A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether use of Recombinant Activated Factor VII could help haemostasis for intractable bleeding, and decrease blood or blood product requirements in patients undergoing cardiac surgery without excessive risk from thrombosis. Altogether 129 papers were identified using the reported search strategy of which 13 represented the best evidence on the topic. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that Factor VIIa has proven efficacy and safety in over 400,000 uses worldwide outside the cardiothoracic surgical arena, mostly in haemophiliacs. Results from this experience show a 1% risk of serious thrombotic complications. In the cardiothoracic literature, there have been more than 160 reports of its use for intractable bleeding and the serious complication rate is again around 1-2%. In addition, it has been found to be highly efficacious in 80-90% of cases with a single dose of 60-90 mgykg, which can be repeated after 2-4 h. Thus, for patients with intractable bleeding post cardiac surgery refractory to conventional haemostatic interventions, Factor VIIa is recommended and its complication rates are low.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS w1x.
Clinical scenario
You are with a 72-year-old patient who is 15 h post emergency Type A dissection repair and CABGx1. It was a difficult operation with a long bypass time. Post-operatively he has been bleeding profusely. He has been reopened but no bleeding points have been found, and he has returned to the CICU packed and with the chest open. He has received 12 units of fresh frozen plasma and 2 pools of platelets and cryoprecipitate, but has still bled 400 ml per hour for the last 3 h. You discuss the patient with the haematologist and he tells you that they now have recombinant activated Factor VII available for use, and asks whether you would like to use it. He has no experience with this post-cardiac surgery and neither have you and you are a little anxious about the patency of the graft that you had to place, but you elect to give it and then search for reports of its use. *Corresponding author. Tel.yfax: q44 780 1548122. E-mail address: joeldunning@doctors.org.uk (J. Dunning).
Three-part question
In wpatients with intractable post-operative bleedingx, does wRecombinant Activated Factor VIIx reduce wpost-operative bleeding without causing significant complicationsx?
Search strategy
Medline 1966-April 2006 using the OVID interface. wFactor VII$.mp or exp factor VIIayOR novoseven.mp OR eptacog alpha.mpx AND wcardiac surgery.mp OR cardiopulmonary bypass.mp OR Heart transplant.mp OR exp Cardiac surgical proceduresyOR exp Coronary artery bypassyOR exp heart transplantationyx AND wexp blood loss,surgicalyOR postoperative haemorrhage.mp OR bleeding.mp OR transfusion.mp OR Coagulopathy.mpx
Search outcome
A total of 129 papers were identified using the reported search from which 13 represented the best evidence to answer the question. Of note case reports and paediatric cases were excluded. The papers are summarised in Table  1 w2-14x.
Results

Roberts et al. in 2004
w12x published a review of the current use of Factor VIIa across all specialties. Over (Continued on next page) 400,000 uses have been recorded, mostly in haemophiliacs, and its risk of serious adverse events was estimated as under 1%. The risk of non-serious treatment related adverse events was estimated as 8-13%. The usual dose was 90 mgykg, but larger doses of 320 mgykg have also been recorded without major adverse effects. Levi et al. in 2005 w3x performed a systematic review of the efficacy and safety of recombinant Factor VIIa. They identified 28 clinical trials and 300 other case reports and series including 1854 patients. In haemophiliacs over 90% efficacy has been well demonstrated at a dose of 90 mgykg in 156 articles. If after 2-3 h bleeding continues, then an infusion of 16.5 mgykg may also be started. In a further 37 patients with severe bleeding they reported a 60% efficacy in bleeding reduction and reported that an RCT of 301 patients with severe blunt trauma that is soon to report will show significant reduction in RBC use, a 5% reduction in mortality (NS) and a trend to less organ dysfunction. They pooled the adverse event rates in nonhaemophiliac and estimated the risk of thromboembolism to be 1.4%. Thus, Factor VIIa has been well tested and its safety established in haemophiliacs and non-cardiac surgical patients.
In the Cardiothoracic Literature, Diprose et al. have performed the only randomised controlled trial in high-risk patients pre-cardiac surgery w4x. They intended to recruit 32 patients for each arm, but unfortunately were unable to secure full funding for this. They eventually had 10 patients in their Factor VIIa arm and 10 placebo patients. The mean drain loss was halved (630 ml down to 330 ml) and blood product usage was 13 units in the Factor VIIa arm compared to 105 in the placebo arm. In a second paper by the authors they reported dramatic reductions in blood loss in 17 patients when Factor VIIa was used as rescue treatment in patients with very high blood loss post cardiac surgery w5x.
Karkouti w8x reported 51 patients with intractable bleeding post cardiac surgery, who received between 35 and 70 mgykg of Factor VIIa after at least 2000 ml blood loss, platelets and FFP. They reported a significant reduction in blood loss, and a substantial reduction in the use of blood products. Four people had a stroke, but one had loose atheroma in the aortic arch and two had a significant period of cerebral hypoperfusion.
Aggarwal et al. w10x reported the results of 24 patients post cardiac surgery who received 90 mgykg of Factor VIIa for intractable bleeding. There was a significantly lower requirement for blood and blood products after administration. Only 6 patients survived to discharge and one patient suffered a subclavian DVT in a vein with a central line.
Von Heymann et al. reported 24 patients who had Factor VIIa for intractable bleeding post cardiac surgery w6x. They also identified a retrospective cohort for comparison. No thrombotic complications were seen and 18 of 24 patients reduced their blood loss to -100 mlyh. Interestingly in the control group where routine treatment had been given, 17 reduced their blood loss by a similar amount.
Hyllner w7x reported 24 cases of Factor VIIa use in postcardiac patients with intractable bleeding. They reported that there was a significant reduction in blood loss, and no patients exsanguinated. There were also no thrombotic complications.
In the remaining studies, Bishop w2x reported 12 patients, Vanek w9x reported 7 patients, Halkos w11x reported 9 patients, Al Douri w14x 4 cases and DiDomenico w13x 2 cases of the use of Factor VIIa for intractable bleeding post cardiac surgery. DiDomenico et al. in their review reported a case of ECMO circuit and cardiac thrombosis, which resulted in death and a possible mediastinal thrombosis, but no other complications were documented in the other studies.
Conclusion
Factor VIIa has proven efficacy and safety in over 400,000 uses worldwide outside the cardiothoracic surgical arena, mostly in haemophiliacs. Results from this experience show a 1% risk of serious thrombotic complications. In the cardiothoracic literature there have been more than 160 reports of its use for intractable bleeding and the serious complication rate is again around 1-2%. In addition, it has been found to be highly efficacious in 80-90% of cases with a single dose of 60-90 mgykg which can be repeated after 2-4 h. Thus, for patients with intractable bleeding post cardiac surgery refractory to conventional haemostatic interventions, Factor VIIa is recommended and its complication rates are low.
